PRCT Stock Summary and Trading Ideas (Procept Biorobotics | NASDAQ:PRCT)

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Procept Biorobotics trades on the NASDAQ stock market under the symbol PRCT.

As of March 2, 2026, PRCT stock price climbed to $23.26 with 809,481 million shares trading.

PRCT has a beta of 1.14, meaning it tends to be more sensitive to market movements. PRCT has a correlation of 0.16 to the broad based SPY ETF.

PRCT has a market cap of $1.30 billion. This is considered a Small Cap stock.

Last quarter Procept Biorobotics reported $76 million in Revenue and -$.53 earnings per share. This fell short of revenue expectation by $-17 million and missed earnings estimates by -$.21.

In the last 3 years, PRCT traded as high as $103.81 and as low as $19.35.

The top ETF exchange traded funds that PRCT belongs to (by Net Assets): VTI, VB, IWM, VBK, VXF.

PRCT has underperformed the market in the last year with a price return of -64.2% while the SPY ETF gained +18.5%. PRCT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.6% and -16.3%, respectively, while the SPY returned +1.2% and +0.6%, respectively.

PRCT support price is $21.87 and resistance is $23.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRCT shares will trade within this expected range on the day.